TrialStem cell research & therapy2021

Management of toxic optic neuropathy via a combination of Wharton's jelly-derived mesenchymal stem cells with electromagnetic stimulation.

Emin Özmert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.